Deback Claire, Burrel Sonia, Varnous Shaïda, Carcelain Guislaine, Conan Françoise, Aït-Arkoub Zaïna, Autran Brigitte, Gandjbakhch Iradj, Agut Henri, Boutolleau David
INSERM UMR S996 and AP-HP, Hôpitaux Universitaires Paris-Sud, Service de Virologie, Villejuif, France.
Antivir Ther. 2015;20(2):249-54. doi: 10.3851/IMP2818. Epub 2014 Jun 25.
Cytomegalovirus (CMV) remains a leading cause of morbidity after solid organ transplantation. The efficiency of antivirals for the treatment of CMV infections may be hampered because of the emergence of CMV resistance to antivirals. The development of CMV multidrug resistance, which remains uncommon but does occur, constitutes a clinically challenging complication and may contribute to difficult therapeutic management and adverse clinical outcome. We report here the observation of the emergence of a multidrug-resistant CMV infection in a heart-transplant recipient and review the literature on similar cases to identify the potential strategies for the successful management of CMV multidrug resistance among immunocompromised patients.
巨细胞病毒(CMV)仍然是实体器官移植后发病的主要原因。由于CMV对抗病毒药物产生耐药性,抗病毒药物治疗CMV感染的效率可能会受到影响。CMV多药耐药的发生虽仍不常见但确有发生,这构成了一个具有临床挑战性的并发症,可能导致治疗管理困难和不良临床结局。我们在此报告一名心脏移植受者中出现多药耐药CMV感染的观察结果,并回顾类似病例的文献,以确定免疫功能低下患者成功管理CMV多药耐药的潜在策略。